INDAPTA THERAPEUTICS
Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.
INDAPTA THERAPEUTICS
Industry:
Biopharma Biotechnology Medical
Founded:
2017-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.indapta.com
Total Employee:
11+
Status:
Active
Total Funding:
50 M USD
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
Enterin
Philadelphia-based biotechnology company .
Escient Pharmaceuticals
Escient Pharmaceuticals is a privately held biotechnology company.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Eyebiotech
Eyebiotech is a privately held ophthalmology biotechnology company.
Libra Therapeutics
Libra Therapeutics is a biotechnology company.
MOMA Therapeutics
MOMA Therapeutics operates as a biotechnology company.
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Current Advisors List
Current Employees Featured
Investors List
Leaps by Bayer
Leaps by Bayer investment in Series A - Indapta Therapeutics
Lonza
Lonza investment in Series A - Indapta Therapeutics
Myeloma Investment Fund
Myeloma Investment Fund investment in Series A - Indapta Therapeutics
RA Capital Management
RA Capital Management investment in Series A - Indapta Therapeutics
Vertex Ventures
Vertex Ventures investment in Series A - Indapta Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-10 | Indapta snags $50M financing and signs on former Juno exec as CEO |
Official Site Inspections
http://www.indapta.com Semrush global rank: 5.84 M Semrush visits lastest month: 1.42 K
- Host name: 83.162.211.130.bc.googleusercontent.com
- IP address: 130.211.162.83
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Indapta Therapeutics"
Indapta
Indapta has developed a proprietary process to expand g-NK cells that yields a highly potent product without the need for artificial genetic engineering. The companyโs first-in-human โฆSee details»
Org Chart Indapta Therapeutics - The Official Board
Organizational Chart of Indapta Therapeutics. Indapta Therapeutics www.indapta.com. has 11 executives +1 408 568 4292; Add an executive. Indapta Therapeutics News . Anything โฆSee details»
Indapta Therapeutics - Crunchbase Company Profile & Funding
Organization. Indapta Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Covers the use of Indapta Therapeutics' โฆSee details»
Indapta Therapeutics - The Org
Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRฮณ-deficient natural killer (G-NK) cell therapy to treat โฆSee details»
Indapta Therapeutics - Overview, News & Similar companies
Feb 10, 2022 View Indapta Therapeutics (www.indapta.com) location in Washington, United States , revenue, industry and description. Find related and similar companies as well as โฆSee details»
Indapta Therapeutics Company Profile 2024: Valuation, Funding ...
Indapta Therapeutics was founded in 2017. Where is Indapta Therapeutics headquartered? Indapta Therapeutics is headquartered in San Francisco, CA. What is the size of Indapta โฆSee details»
Indapta Therapeutics' Leadership Team - The Org
The leadership team at Indapta Therapeutics has a wealth of experience in the biotech industry. The team's founder has experience as a VP of Intellectual Property/Gov't Affairs and as a โฆSee details»
Indapta Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Indapta Therapeutics Inc. of Houston, TX. Get the latest business insights from Dun & Bradstreet.See details»
INDAPTA
Indapta Value Proposition Universal G-NK Cell Platform. Created Date: 1/24/2024 5:36:43 AM ...See details»
Indapta Therapeutics Announces Key Management Team โฆ
Feb 3, 2021 Indapta Therapeutics Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat โฆSee details»
Indapta - Company Profile - Tracxn
Indapta - Limited information available. Raised a total funding of $72.5M over 2 rounds from 6 investors. Indapta has 402 competitors.See details»
Indapta Therapeutic - VentureRadar
Indapta is a biotechnology company harnessing the natural power of the immune system to fight hematologic and solid cancers with its universal natural killer (NK) cell platform derived from โฆSee details»
Indapta Therapeutics - Craft
Indapta Therapeutics is a biotechnology company, which is focused on developing and a proprietary, off-the-shelf, allogeneic FcRฮณ-deficient natural killer (G-NK) cell therapy to treat โฆSee details»
Indapta Therapeutics (USA) Funding: $54.5M - Medical Startups
Dec 19, 2024 Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRฮณ-deficient natural killer (G-NK) cell โฆSee details»
Houston startup secures $22.5M to innovate cell therapy to fight โฆ
Dec 26, 2024 A promising cell therapy company has raised its latest funding round โ to the tune of $22.5 million. Indapta Therapeutics, which has a dual headquarters in Houston and Seattle, โฆSee details»
Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief โฆ
Indaptaโs off-the-shelf G-NK cell therapy is further differentiated from other NK cell therapies in that it is a cell banked product with low variability. In vivo studies have demonstrated the safety โฆSee details»
Indapta - Raised $72.5M Funding from 6 investors - Tracxn
Indapta has raised a total funding of $72.5M over 2 rounds from 6 investors. Investors include RA Capital Management, Pontifax and 4 others. Their latest funding round was of $22.5M on Dec โฆSee details»
Indapta raises another $22.5 million for cell therapies
Dec 18, 2024 Indapta Therapeutics raises $22.5 million to advance clinical trials for IDP-023, its g-NK cell therapy platform targeting cancer and autoimmune diseases. The funding supports โฆSee details»
Indapta Therapeutics Provides Corporate Update
Jul 7, 2020 Indaptaโs off-the-shelf G-NK cell therapy is further differentiated from other NK cell therapies in that it is a cell banked product with low variability. In vivo studies have โฆSee details»
Microsoft Word - MMRF Indapta Press Release_10 28 20 FINAL.docx
Oct 28, 2020 Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat ...See details»